Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06251310 · ClinicalTrials.gov registry record · Phase 1

SW-682 in Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor and Mesothelioma, Malignant, sponsored by SpringWorks Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
186
Enrollment target
8
Study locations

NCT06251310: Recruiting Phase 1 study of Advanced Solid Tumor and Mesothelioma, Malignant, sponsored by SpringWorks Therapeutics.

NCT06251310 is a Phase 1 study of Advanced Solid Tumor and Mesothelioma, Malignant that is actively recruiting participants, run by SpringWorks Therapeutics. The registered enrollment target is 186 participants, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target. The trial reports 8 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06251310, a Phase 1 study of Advanced Solid Tumor and Mesothelioma, Malignant, is actively recruiting participants, sponsored by SpringWorks Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
186 participants
Enrollment target
8
Study locations

Study Summary

This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after appropriate prior systemic anticancer therapy, including chemotherapy, immunotherapy, radiation therapy or targeted therapy, or for which no treatment is available, or prior standard of care (SOC) therapy was not tolerated and for which there is no further SOC treatment available. The study includes a Part 1 (Phase 1a) dose escalation phase and a Part 2 (Phase 1b) dose expansion to optimize the dose to be used for further development. All participants will self-administer SW-682 by mouth in 28-day cycles.

Primary Outcome

Safety and tolerability endpoint evaluation via incidence of dose limiting toxicities (DLTs), serious adverse events (SAEs), treatment emergent adverse events (TEAE)

Conditions Studied

Advanced Solid Tumor Mesothelioma, Malignant

Interventions

  • DRUG SW-682
  • DRUG Combination Therapy

Study Locations (8)

California

  • UC San Diego Moores Cancer Center - La Jolla
  • USC/Norris Comprehensive Cancer Center - Los Angeles
  • SpringWorks Clinical Trial Site - Los Angeles

Texas

  • Mary Crowley Cancer Research - Dallas
  • The University of Texas MD Anderson Cancer Center - Houston

Arizona

  • SpringWorks Clinical Trial Site - Scottsdale

Ohio

  • University Hospitals Cleveland Medical Center - Cleveland

Oregon

  • Knight Cancer Institute Clinical Trials - Portland

Trial Details

FieldValue
Enrollment Target 186 participants
Start Date 2024-07-30
Est. Completion 2030-06
Phase Phase 1
SpringWorks Therapeutics

7 total trials

What NCT06251310 shows while recruiting

NCT06251310 is an interventional study that assigns participants to a tested intervention. The registered 186 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target.

The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which SW-682 is the first listed.

NCT06251310 lists 8 locations in 5 states (California, Texas, Arizona).

Frequently Asked Questions

What is clinical trial NCT06251310 about?

NCT06251310 is a clinical study titled "SW-682 in Advanced Solid Tumors". This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after ap...

What is the current status of trial NCT06251310?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 186 participants. The study started on 2024-07-30. Estimated completion is 2030-06.

What conditions does trial NCT06251310 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Mesothelioma, Malignant.

What interventions are being tested in trial NCT06251310?

The interventions under investigation include: SW-682 (DRUG), Combination Therapy (DRUG).

Who is sponsoring clinical trial NCT06251310?

This trial is sponsored by SpringWorks Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06251310 being conducted?

This trial has 8 study locations across Arizona, California, Ohio, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06251310's enrollment target sits among peer trials

186 71st of 189 higher than 119 of 189 other Advanced Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03567889 · 186 participants · Phase 3

    Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients

  • NCT05281471 · 186 participants · Phase 3

    Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

  • NCT05405595 · 186 participants · Phase 1

    ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

  • NCT05762107 · 186 participants · Phase 2

    A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06251310

Source: ClinicalTrials.gov NCT06251310, the US trial registry maintained by the National Library of Medicine. NCT06251310 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.